stemmacolore
Cerca

Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Stato
Autorizzato - In attesa di apertura
Codice studio
AV-299-23-301
Codice EudraCT
2023-505606-42
Sponsor/Promotore
AVEO Pharmaceuticals, Inc.
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator
Dott.ssa Mariagrazia Ghi
Torna in alto